Stable Angina

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/22

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 2:05 AM on 7/6/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

23 Terms

1
New cards

Define angina. What is the difference between stable and unstable angina?

Angina - chest pain, pressure or discomfort usually caused by ischemia of the heart muscle

Stable angina - predictable chest pain, brought on by exertion or emotional stress, relieved within minutes by rest or short-acting nitroglycerin

Unstable angina (UA) - chest pain increases (in frequency, intensity or duration) and is NOT relieved with nitroglycerin or rest

2
New cards

Describe the pathophysiology of stable angina.

Angina = Oxygen demand > Oxygen supply

Demand increases with:

  • ↑ Heart rate

  • ↑ Contractility

  • ↑ Preload

  • ↑ Afterload

Supply decreases with:

  • Coronary artery disease (atherosclerosis)

  • Coronary artery vasospasm

    • Can occur at rest or caused by illicit drug use (cocaine)

3
New cards

What type of tests are used to diagnose stable angina and assess likelihood of CAD?

1) Cardiac stress test

  • Increases myocardial oxygen demand with exercise or IV meds and monitors pt for sx of chest pain, SOB, lightheadedness, changes in HR/BP, ECG abnormalities

2) Coronary angiography

  • Performed to assess the extent of atherosclerosis and need for revascularization

4
New cards

Describe the treatment approach for stable angina.

1) Antiplatelet (for secondary prevention)

  • Aspirin - recommended antiplatelet

  • Clopidogrel used when there is allergy or CI to aspirin

  • DAPT NOT useful for secondary prevention in pts with stable angina

    • Recommended only after recent ACS or percutaneous coronary intervention (PCI)

2) Antianginal (reduce chest pain)

3) BB, DHP / non-DHP CCB, long-acting nitrates

  • Prevent symptoms

4) Ranolazine can be added if needed after above therapies

5) Short-acting nitroglycerin (SL) or TL spray

  • Recommended for immediate relief of angina in ALL pts

5
New cards

Aspirin MOA

Irreversibly inhibits COX-1 and COX-2 enzymes —> ↓ prostaglandin (PG) and thromboxane A2 (TXA2) production

  • TXA2 is a potent vasoconstrictor and inducer of platelet aggregation

6
New cards

Aspirin CI

NSAID or salicylate allergy

Children and teenagers with viral infection (due to risk of Reye’s syndrome) - sx of somnolence, N/V, and confusion

7
New cards

Aspirin warnings / SEs/ monitoring

Warnings

  • Bleeding

  • Tinnitus (a sign of salicylate overdose)

SEs

  • Dyspepsia, heartburn, bleeding, nausea

Monitoring

  • Sx of bleeding, bruising

8
New cards

How long does a pt have to be on aspirin when used for stable angina? Why?

Used indefinitely in stable angina: ↓ CV events and death

9
New cards

What form of aspirin is preferred in ACS?

  • Non-enteric coated, chewable aspirin

  • If only enteric-coated aspirin availble, should be chewed (325mg)

10
New cards

What drug can be used to protect the GI tract from chronic aspirin use?

PPIs

  • Consider risk vs benefits

    • Risks: ↓bone density, ↑infection risk

11
New cards

Clopidogrel MOA

Prodrug that irreversibly inhiits P2Y12 ADP-mediated platelet activation and aggregation

12
New cards

Clopidogrel boxed warning

Prodrug

  • Effectiveness depends on conversion to active metabolite via CYP450 2C19

    • If poor metabolizer, consider other treatments

13
New cards

Clopidogrel CI / warnings/ SEs/ monitoring

CI

  • Serious bleeding (GI bleed, intracranial hemorrhage)

Warnings

  • Bleeding risk

  • DO NOT use with omeprazole or esomeprazole

    • Omeprazole/esomeprazole: CYP2C19 inhibitors

  • Premature discontinuation (↑ risk of thrombosis)

  • Thrombotic thrombocytopenia purpura (TTP)

    • Small blood clots forming in many small blood vessels throughout the body

SEs

  • Bleeding

Monitoring

  • Symptoms of bleeding, Hgb/Hct as necessary

14
New cards

Clinical benefit of beta blockers as antianginal treatment.

Reduce oxygen demand from heart: ↓ HR, ↓ contractility, ↓left ventricular wall tension

15
New cards

In what type of angina should BB be avoided?

Avoid in vasospastic angina

  • Use CCB instead

16
New cards

Clinical benefit of CCB as antianginal treatment

  • Reduce myocardial oxygen demand: non-DHPs ↓ HR and contractility; DHPs ↓ SVR (afterload)

  • Slow release/long acting preferred

    • AVOID nifedipine IR

  • DHPs preferred when used with BB compared to non-DHPs

    • Risk of bradycardia

17
New cards

Clinical benefit of nitrates as antianginal treatment

  • ↓ preload (free radical nitric oxide produces vasodilation of veins more than arteries)

  • Fast relief for chest pain

18
New cards

Nitrate CI

Do not use with PDE-5 inhibitors

19
New cards

Nitrate warnings / SE/ monitoring

Warnings

  • Hypotension

  • Tachyphylaxis (tolerance/↓effectiveness)

SE

  • HA, flushing, syncope, dizziness

Monitoring

  • BP, HR, chest pain

<p>Warnings</p><ul><li><p>Hypotension</p></li><li><p>Tachyphylaxis (tolerance/↓effectiveness) </p></li></ul><p>SE</p><ul><li><p>HA, flushing, syncope, dizziness </p></li></ul><p>Monitoring </p><ul><li><p>BP, HR, chest pain </p></li></ul><p></p>
20
New cards

Long acting nitrates require a nitrate free interval. Why? How long is patch, ointment, and isosorbide mononitrate dosed?

21
New cards

Ranolazine MOA

Selectively inhibits late phase Na current and ↓ intracellular Ca

  • ↓ ventricular tension

22
New cards

Ranolazine CI / warnings / SEs/ monitoring

CI

  • Liver cirrhosis; don’t use with strong CYP3A4 inhibitors or inducers

Warnings

  • QT prolongation

  • Acute renal failure observed when CLcr < 30 mL/min

SEs

  • Dizziness, HA, constipation, nausea

Monitoring

  • ECG, K, renal function

23
New cards

What is the major drug interaction with ranolazine?

Ranolazine is a major CYP3A4 substrate and minor CYP2D6 and pgp substrate

  • DO NOT use with strong CYP3A4 inhibitors or inducers